Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressants and suicidal risk.

B Müller-Oerlinghausen1, A Berghöfer

  • 1Department of Psychiatry, Freie Universität Berlin, Germany. bmoe@zedat.fu-berlin.de

The Journal of Clinical Psychiatry
|March 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same author

Letter of response to Nabi Z, Stansfeld J, Plöderl M, Wood L, Moncrieff J. Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. <i>Epidemiol Psychiatr Sci</i>. 2022 Sep 16;31:e65. doi: 10.1017/S204579602200049X.

Epidemiology and psychiatric sciences·2022
Same author

[Stopping antidepressants: withdrawal symptoms and rebound effects : Review and practical recommendations].

Der Nervenarzt·2022
Same author

Occurrence and determinants of parental psychosocial stress and mental health disorders in parents and their children in early childhood: rationale, objectives, and design of the population-based SKKIPPI cohort study.

Social psychiatry and psychiatric epidemiology·2020
Same author

Efficacy of Parent-Infant-Psychotherapy with mothers with postpartum mental disorder: study protocol of the randomized controlled trial as part of the SKKIPPI project.

Trials·2020
Same author

Prediction of lithium response using clinical data.

Acta psychiatrica Scandinavica·2019

Antidepressant underprescription and treatment failure are greater concerns than drug toxicity. While some antidepressants may increase suicidal behavior, lithium prophylaxis shows promise in reducing suicide risk for affective disorders.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Psychology

Background:

  • Antidepressant use in suicidal patients is limited, with underprescription and treatment failure posing significant clinical challenges.
  • Concerns exist regarding antidepressants, including selective serotonin reuptake inhibitors (SSRIs), potentially increasing suicidal behavior by energizing patients or inducing akathisia.
  • The efficacy and safety of various antidepressant classes require careful consideration in managing suicidal ideation and behavior.

Purpose of the Study:

  • To evaluate the practical importance of antidepressant underprescription and treatment failure versus drug toxicity in suicidal patients.
  • To assess the role of different antidepressant classes, including SSRIs and tricyclics, in suicidal behavior.
  • To examine the efficacy of lithium prophylaxis and other mood stabilizers in reducing suicide risk and mortality in affective disorders.

Related Experiment Videos

Main Methods:

  • Review of clinical data and evidence from large international sources and multicenter controlled trials.
  • Analysis of antidepressant prescribing patterns and treatment outcomes in suicidal patient populations.
  • Comparative assessment of selective serotonin reuptake inhibitors (SSRIs), tricyclics, lithium, and non-lithium mood stabilizers regarding suicide prevention.

Main Results:

  • Antidepressant underprescription and treatment failure are more significant issues than the toxicity of prescribed agents.
  • Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants may paradoxically increase suicidal behavior in some patients.
  • Lithium prophylaxis has demonstrated a reduction in suicide risk and overall mortality in patients with affective disorders.
  • Clinical trials have not confirmed the superiority of SSRIs over tricyclics in reducing suicide attempts.
  • A conclusive suicide-preventing effect for antidepressants or non-lithium mood stabilizers remains undemonstrated.

Conclusions:

  • Addressing antidepressant underprescription and optimizing treatment strategies are crucial for managing suicidal patients.
  • Careful selection of antidepressants, considering potential risks like akathisia and energizing effects, is necessary.
  • Lithium prophylaxis appears to be a valuable intervention for reducing suicide risk and mortality in affective disorders, warranting further investigation for other mood stabilizers.